Surviving and Thriving in Due Diligence – Major Transactions from the Perspective of Small Pharma, Upcoming Webinar Hosted by Xtalks

Share Article

A challenge many small pharmaceutical companies face is how to successfully commercialize their drug product. Often, companies may need to license their pharmaceutical assets, sell the company or make an initial public offering (IPO). These processes involve due diligence, a procedure that may seem daunting to companies that have little experience with deal-making. In this free webinar, learn about basic due diligence concepts, different types of pharmaceutical patents and other common inquiries that small pharmaceutical companies might have.

Xtalks Life Science Webinars

This webinar will take the attendees through the due diligence process through the eyes of a small company interested in making a transaction with its intellectual property.

Join Eyal Barash, JD, Attorney at Law, Barash Law, LLC in a live webinar on Wednesday, February 12, 2020 at 1pm EST to hear about:

  • An overview of the due diligence process from a small company’s point of view
  • Different classes of pharmaceutical patents
  • Value drivers for each class of patent
  • Due diligence concepts around inventorship, chain of title and scope of filing
  • Common due diligence inquiries (e.g. patent validity, infringement, design-arounds)

Innovation in drug discovery often starts in universities or with small enterprises. While the initial research and discovery are well within the purview of many university labs and small companies, advanced clinical development and commercialization are often well beyond the means of such entities. In order to bring drugs to market, smaller companies have to make enormous investments to build infrastructure (i.e. through public offerings), license their valuable pharmaceutical assets or simply sell the company to more established players who have the bandwidth for successful commercialization.

Patents provide exclusionary rights without which there is often insufficient barrier to competition to warrant investment. As a result, sophisticated investors and acquirers devote substantial resources to perform due diligence, which refers to research on financial analysis, clinical efficacy, human resource investigations and intellectual property, on patent assets they are considering for deal-making.
This webinar will take the attendees through the due diligence process through the eyes of a small company interested in making a transaction with its intellectual property. As such, this webinar will be appropriate for senior-level executives such as CEOs, CFOs, VPs of business and in-house counsel working at small to medium-sized pharma companies or law firms with corporate transaction teams.

For more information or to register for this event, visit Surviving and Thriving in Due Diligence – Major Transactions from the Perspective of Small Pharma.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 x 400
Email: ctang@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
+1 (416) 977-6555 x 400
Email >
Visit website